Aldafermin produces fibrosis regression in NASH

Patients with nonalcoholic steatohepatitis with advanced fibrosis experienced fibrosis regression after treatment with aldafermin, according to research presented at The Liver Meeting Digital Experience.In his presentation, Guy W. Neff, MD, from Covenant Research, said aldafermin (NGM Biopharmaceuticals), and FGF19 analogue, has previously been tested in three patient cohorts for a treatment period of 12 weeks in various doses. Neff’s presentation comprised a subgroup analysis of the fourth study cohort, with evaluated 1 mg of the drug for 24 weeks compared with placebo. Specifically,Read More

Share on facebook
Share on twitter
Share on linkedin